DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 AstraZeneca’s Danicopan Trial; CHMP Recommends Sanofi/AstraZeneca’s nirsevimab; Akero’s NASH Drug Trial; FDA Grants Orphan Drug Status to SY-5609; BMS’s Opdivo Trial Results; Pfizer to File for FDA Approval for Meningitis Vaccine; EMA Orphan Drug Designation to CAN-2409; FDA Starts Priority Review of Chiesi ‘s velmanase alfa Visit Post
2 Aktis’s Novel Targeted Alpha Radiopharmaceuticals; Koye Partners with Sonde Health; Novartis to Spin Off Sandoz Business; Alcon to Buy Aerie Pharma; Fast Track Designation to Merck’s MK-2060; FDA Approves Ibrutinib for Chronic GvHD; French Authorities Clears BrainVectis’s Clinical Trial; Takeda’s Dengue Vaccine TAK-003 Gets Approval in Indonesia Visit Post
3 EMA to review Cidara Therapeutics’ Rezafungin; EU Approves Gilead Sciences’ Sunlenca; FDA Approves Axsome’s Auvelity; EU Marketing Authorisation to Oncopeptides’s Pepaxti; Merck Signs $ 3.5 B Deal with Orna; FDA to review AstraZeneca and Merck’s Lynparza; FDA Approval to Bluebird’s Zynteglo; FDA Decision Date for GSK’s Momelotinib Visit Post
4 CereVasc’s eShunt System Study; FDA Approves NGS-Based CDx for Trastuzumab Deruxtecan; Nanopath Secures $10 Million Funding; BD, Accelerate Diagnostics Announce Collaboration; Avails Medical’s Clinical Trials for eQUANT; Movano Ring Exceeds Accuracy Targets for SpO2 & Heart Rate Monitoring Visit Post
5 Bristol-Myers Squibb’s Opdivo & Yervoy Combo Trial; Sarepta’s Gene Therapy SRP-9001 for DMD; Ionis’s End-Stage Renal Disease Drugs; FDA Approves Arcutis’s Zoryve Cream; Gilead’s Biktarvy for HIV and Hepatitis B; FDA to Review Biogen’s ALS Therapy Tofersen Visit Post
6 Zsquare ENT-Flex Rhinolaryngoscope Receives FDA Clearance; ClearMind Biomedical's Completion of Least Invasive ICH Treatment; Bruker Launched Tool for ‘Long COVID’ Multi-Organ Risk Assessment; EarlySign, Roche Signed Strategic Deal; FDA Clearance for Leva® Pelvic Health System; NeuroOne’s Evo® sEEG Electrode Visit Post
7 Comprehensive Assessment of the Leading Companies in the Vaccines Market Visit Post
8 Chlamydia Treatment: Is it the End of the Antibiotic Era? Visit Post
9 GenScript Enters Distribution Agreement with EUROIMMUN; Biomerics’s New Facility in Galway (Ireland); MedAlliance’s SELUTION SLR DEB; OmniGuide’s RevoLix HTL Hybrid Thulium Laser; Filterlex’s CAPTIS Full-Body Embolic Protection Device; Orthofix’s M6-C Artificial Cervical Disc Visit Post
10 Assessing the Growing Challenge of MONKEYPOX and How Pharma Companies are Responding? Visit Post
11 Abbott’s Alinity m STI Assay; Phillips’ MR 7700 System; HOYA’s MiYOSMART Spectacle Lens; Magneto’s Pulmonary Embolism Treatment; Owen Mumford and Stevanto Group’s Collaboration Deal; Elekta’s Radiosurgery System-Elekta Esprit Visit Post
12 GE and Medtronic's Collaboration; Vivalink's Multi-Vital Blood Pressure Patch; Foldax's TRIA Biopolymer Surgical Aortic Heart Valve; Vektor Medical's vMap Clinical Validation Study; iSono's ATUS System; Mirvie's Test to Identify Risk of Preeclampsia Visit Post
13 GSK Acquires Sierra Oncology; BriaCell’s Targeted Breast Cancer Immunotherapy; Merck’s Tepmetko; Gilead’s Magrolimab for MDS and AML; Eli Lilly’s Retevmo; Merck’s Pneumococcal Vaccine; FDA Approves Bevacizumab Biosimilar; Halozyme to Acquire Antares Pharma Visit Post
14 BioXcel’s Agitation Drug Igalmi; FDA Approves Cysteine Hydrochloride Injection; Gilead’s Trodelvy; Alembic Pharma’s Topical Anesthetic Cream; Pfizer Acquires ReViral; Telix Buys Lilly's Failed Cancer Drug Lartruvo Visit Post
15 Sanofi’s Rare Disease Drug Xenpozyme' Approval; FDA Approves Novartis’ Pluvicto; AstraZeneca’s Imfinzi Trial Result; FDA’s Green Signal to Argenx’ Vyvgart; ViiV Healthcare and J&J’s HIV Treatment Cabenuva; UCB's FINTEPLA Approval; Cullinan’s Update for CLN-081; MEI Pharma & Kyowa’s Zandelisib Approval Visit Post
16 Smithfield BioScience and BioCircuit’s Nerve Tape Device; Cynosure-Jeisys Medical’s Partnership; bioMérieux’s VITEK® MS PRIME new MALDI-TOF Mass Spectrometry Identification System; Artio Medical’s Gold Embolization Device; Heartpoint Global's Implant System; ObvioHealth’s Virtual Urogynecology Clinical Trial Visit Post
17 Bristol Myers’ Opdivo combo Opdualag for Melanoma; Biogen’s Aduhelm; Marinus’ Ztalmy for CDKL-5 Deficiency Disorder; Merck’s Keytruda + Lynparza; Vitaris’s Breyna; Moderna’s Second COVID-19 Booster Shot; Takeda’s Exkivity; BMS’s First LAG-3 Checkpoint Inhibitor Visit Post
18 AstraZeneca and Merck’s Lynparza; Venatorx’s cefepime-taniborbactam; AbbVie’s Qulipta; AstraZeneca’s IL-5 inhibitor Fasenra; Sandoz Acquires Coalesce; Incyte’s Opxelura; Bayer’s Nubeqa; NICE Rejects Keytruda Plus Chemotherapy Visit Post
19 Noninvasix’s LIVOx™ Central Venous Oxygenation Monitor; LivaNova’s aura6000 System; Oxford BioDynamics’s EpiSwitch® CiRT; Masimo’s SedLine® Brain Function Monitoring and the SedLine Pediatric EEG Sensor; Medtronic’s NuVent™ Eustachian Tube Dilation Balloon; Conformis’s published data for Bilateral Knee Implant Study Visit Post
20 GSK’s Covifenz; Idorsia's Quviviq; GSK’s ZEJULA; EMA Expands its Nod for BMS, Eli Lilly, and Novartis Drugs; Cantex Secures Global Licence to Develop Azeliragon; Biocon Acquires Viatris’ Biosimilar Business Visit Post
21 Widespread Usage of HPV Vaccine Reduces Cervical Cancers and Precancers Visit Post
22 Immunocore’s Kimmtrak; Samsung Acquires Biogen's Biosimilar Unit; Novavax’s COVID-19 Vaccine; CHMP Approves Dupixent (dupilumab); Glenmark’s High Blood Pressure Treatment; Roche’s Faricimab; GBT’s Voxelotor Visit Post
23 Merck’s Gefapixant; Pfizer's Somatrogon; Gilead’s Viklury; AbbVie’s Skyrizi; Gilead's Zydelig Approvals; Lantern’s LP-184; Polpharma to Acquire Advent Visit Post
24 Accutar's Phase I clinical trial for AC0176; Bio-Thera's cancer drug, BAT6005; Nykode's Covid-19 vaccine trial; Heat Biologics acquires Elusys Visit Post
25 What are Monoclonal Antibodies and How Can They Treat COVID-19? Visit Post
26 Cerner, Scanwell Health and Personal Genome Diagnostics Acquisition; Zynex's Fluid Monitoring System, CM-1500; Sight Sciences' TearCare System; Envista's Nobel Biocare N1 Implant System Visit Post
27 Sky Medical’s Geko™ device; Fist Assist Devices obtains Breakthrough Device designation; Edwards obtains FDA approval; BD launched instrument for testing; GE acquires BK Medical; Zynex’ CM-1500; Foldax’s TRIA biopolymer heart valve Visit Post
28 Pertussis Vaccines: Whole-cell & Acellular Vaccines, Different Types & Manufacturers along with the Regimen in Various Age Groups Visit Post
29 What is Driving the Pertussis Treatment Market Forward? Visit Post
30 Boston Scientific's MODULAR CRM System; Restore Medical's ContraBand clinical trial result; BD acquires Venclose; Roche differentiates mutations in Omicron; Linus's StrandDx-ASD; HelioLiver launches liquid biopsy test Visit Post
31 LensGen’s Juvene Intraocular Lens; Nevro announces clinical data publications; FDA Clearance to Immunexpress’s SeptiCyte; GE unveils AI and Digital Technologies; Canon launches PIQE DLR and SilverBeam; Hyperfine’s Swoop gets FDA clearance Visit Post
32 GE Healthcare-Optellum's collaboration; Ocugen’s Covid-19 vaccine trial; Blueprint to acquire Lengo Therapeutics; Therapixel's Mammoscreen Visit Post
33 Bluebird bio may get gene therapy approved in the US; Neurocrine pens $2.6B pact with Sosei Heptares; FDA opens clearances for hepatitis C diagnostics; Twist nabs antibody discovery biotech Abveris for $190M Visit Post
34 Top Drugs To Watch in HIV (2025) Visit Post
35 Abbott's Pacemaker System; Ivantis’s Hydrus Microstent; Medtronic’s PillCam Small Bowel 3; ALung Technologies's Hemolung; AppliedVR’s EaseVRx; J&J to split into two companies; OrthAlign’s Lantern® launch; LumiThera’s Light-based Theranostic Visit Post
36 Social Determinants of Health and their Impact on COVID-19 Visit Post
37 Changing Dynamics of HIV-1 Treatment Market Visit Post
38 FDA 510k clearance to Naviswiss's Naviplan; FDA approved to TYRVAYA; Centinel Spine's STALIF Integrated Interbody System; Smith+Nephew's IODOSORB; AlloSource's AlloMend Extra-Large ADM; SpinaFX and StarFish's strategic commercialisation contract Visit Post
39 Analyzing the Emerging Demand for the Probiotics Visit Post
40 Biogen’s AMD Biosimilar Gets Approval; SmartLabs Series B Funding; BARDA, Partner Therapeutics in Sepsis Space; Synlogic to Explore Sepsis Market Domain Visit Post
41 Onychomycosis Therapy Market Set to Balloon Up as Emerging Novel Therapies Continue to Adorn the Space Visit Post
42 Pfizer’s RSV Vaccine; Forte Biosciences’ Atopic Dermatitis Asset; Bone Therapeutics’ Osteoarthritis Programme; JandJ's HIV Vaccine Trial; Versanis Bio $70 M Series A Financing; AC Immune's Alzheimer's Antibody Drug Visit Post
43 Venous Thromboembolism Market Growth Quadrant to Balloon Up Visit Post
44 AstraZeneca's Ultomiris; HebaBiz's Siroquine; Pfizer's XELJANZ; Bristol Myers Squibb's Opdivo; and Masimo's PVi Visit Post
45 Commencement of AAIC; GSK’s Shingles Vaccine Expanded Approval; Pfizer/ BioNtech Agreement with Biovac; Another Failure in Ulcerative Colitis Trial Visit Post
46 Fight Against the Antibiotic Resistance in the Uncomplicated Urinary Tract Infections Market Visit Post
47 MedTech Wrap Up Visit Post
48 Hepion aces mid-stage study; Bicycle Therapeutics-Ionis collaboration; Nimbus raises $105M; Regeneron to support ISA Pharma Visit Post
49 Bayer's CKD Drug; Enochian’s RNA Hijack for HBV; Novo Nordisk's to get Prothena's ATTR Amyloidosis Business; J&J’s COVID-19 Vaccine Struggle Visit Post
50 Charting out the COVID-19 Vaccine Landscape Visit Post
51 Arrowhead's ARO-ENaC Clinical Trial; Sartorius Acquires Stake in CellGenix; AGC Biologics's Cell & Gene Therapy; Sirnaomics Secures $105 Million Visit Post
52 TLX66 in AL Amyloidosis; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; Another Failed NASH Drug Visit Post
53 Pharma Companies Foray into the ABSSSI Market to Develop Novel Antibiotics and Tackle Antibiotic Resistance Visit Post
54 Artios collaborates with Novartis; Scholar Rock eyes Phase III trial; Novavax starts crossover arms in Covid-19 trials; Volastra nabs $44M Visit Post
55 E-Pharmacies: A Disruptive Innovation and the Future of Pharma Sector Visit Post
56 Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega’s Recognition; Roche's Tecentriq Results in NSCLC Visit Post
57 GBT strikes a deal with Sanofi; Lilly's IL-23 inhibitor shows promise; Glooko raises $30M; FDA uplifts hold on Solid’s DMD gene therapy Visit Post
58 Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi/Regeneron’s Libtayo; Roche acquires GenMark; FDA okays Melinta's Kimyrsa Visit Post
59 Novavax targets COVID-19 approval; Iktos collaborates with Pfizer; AbbVie bags option to acquire Mitokinin; Presage inks new pact with Merck Visit Post
60 Applications of AI in Healthcare: COVID-19 and Beyond Visit Post
61 Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval Visit Post
62 The Mesh of the Generics and the Potential of Emerging Therapies in the Smoking Cessation Market Visit Post
63 Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs Visit Post
64 Fake News In The Healthcare Sector: A Misinformation Crisis In The Era Of Digitalization Visit Post
65 Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone Visit Post
66 Aurinia's Lupkynis for Lupus; FDA Fast Track Designation for Toripalimab; Wren Therapeutics’ Financing; Merck’s Covid-19 Vaccine Program End Visit Post
67 Thrombocytopenia Drugs Market: What Newer Agents Are Expected To Enter The Market? Visit Post
68 Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off Visit Post
69 Increasing Prevalence and Upcoming Novel Therapeutic Approaches: What is Shaping the Hepatitis D Market Outlook? Visit Post
70 Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics Visit Post
71 Search for the Cure Continues in the Chronic Hepatitis B Treatment Market Visit Post
72 8 Of The Most Common Foods Allergies - Do You Have One? Visit Post
73 FTA for Gannex’s ASC4; Disappointment for Incyte’s Ruxolitinib; Historic win for Pfizer, BioNTech’s COVID Vaccine; Alexion buyout; the debut of InnoSkel Visit Post
74 AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra's X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3 Visit Post
75 Roche's quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study Visit Post
76 Bioterrorism: A Threat To The Healthcare And Global Peace Visit Post
77 Novartis' COVID-19 deal; Shattered hopes for Remdesivir; Lilly's R&D pact with Precision; Innovent's Humira Biosimilar Visit Post
78 Albireo Pharma's PFIC Therapy; Lupin’s Trichomoniasis Oral Drug; Moderna's Weapon Against COVID; Gilead & Novo Nordisk's Cocktail Therapy for NASH Visit Post
79 FDA authorizes first diagnostic test for Covid-19 antibodies; EGenesis's collaboration with Duke; Pancreatic Cancer research updates; Decibel scores $ 82 M Visit Post
80 Pfizer's COVID-19 Vaccine; Calliditas' NefIgArd trial; ViiV's HIV Prevention Treatment; Biogen’s Aducanumab Rejection Visit Post
81 Fosun-BioNTech's COVID-19 vaccine; Multiple Sclerosis research update; Vosoritide nabs FDA review; FDA nods to paclitaxel-coated Ranger balloon for PAD Visit Post
82 Novartis taps Molecular Partners to combat COVID-19; GSK culls phase 2 asthma drug; Exact Sciences acquires Thrive for $ 2.15 B; EQRx-CStone's deal for checkpoint inhibitors Visit Post
83 Bayer eyes AskBio’s Gene Therapies; Novartis' Iptacopan; Forma's IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic Visit Post
84 GSK's RSV vaccine; SparingVision's interest in gene therapy; InCarda's raise; BridgeBio's R&D deal Visit Post
85 Venclexta full approval; PBP1510 Orphan Status; Roche/ Genesis collab; Immunomodulators for COVID-19 Visit Post
86 Brain's immune cells research update; Moderna's COVID-19 vaccine; Pfizer funnels $200 M into CStone; Myovant's relugolix falls short in metastatic prostate cancer; Alnylam's lumasiran phase 3 result Visit Post
87 Inovio's COVID vaccine trial On-hold; Appeal to Pfizer; XtalPi's massive raise; GSK Nucala's HES approval; J&J's COVID vaccine Visit Post
88 Lilly's COVID-19 antibody reduces hospitalization rate; Tiny biologic drug to combat COVID-19; Aziyo Biologics files for $57.5 M IPO; BMS exercises option on Obsidian's CD40L cell therapy Visit Post
89 While AZ resumes its COVID-19 vaccine trial in the UK; Merck and Gilead are busy making sizeable Breast cancer deals Visit Post
90 Pfizer-BioNTech COVID-19 vaccine trials; OncoImmune raises $56 M; Recursion Pharma nets $239 M; Breast cancer research updates Visit Post
91 Cycle Pharmaceuticals' USD 25M Debt Financing; Bayer’s Phase IV REPLACE Trial; Verona's Pilot Study with pMDI Ensifentrine in COVID Patients Visit Post
92 Nestle to acquire Aimmune Therapeutics; Vir Bio & GSK's COVID-19 monoclonal antibody therapy; AstraZeneca's Farxiga scores goal in Phase III CDK trial Visit Post
93 Moderna's COVID-19 vaccine trial; Freenome secures $270 M; CRISPR treats obesity in mice; Breast cancer research updates Visit Post
94 Novartis’s Spartalizumab Combo Stumbles; Union Therapeutics Doses In COVID-19 Trial; Yumanity To Merge With Proteostasis Visit Post
95 Gilead's remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche's cancer drug Visit Post
96 Infectious Diseases That Possess Significant Challenge To Humans Health Visit Post
97 Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV's peanut allergy patch; Combating COVID-19 with decoy target Visit Post
98 In The Global Race For The COVID-19 Vaccine, India Stands As A Strong Player Visit Post
99 AZ shows positive results for its COVID-19 vaccine; Synairgen offers a new approach to address COVID; GSK, CureVac forms mRNA strategic partnership Visit Post
100 Merck, Dewpoint's HIV Pipeline; Pfizer, BioNTech 's COVID-19 Vaccines; Roche’s Tecentriq- Avastin Duo Failure in Ovarian Cancer Visit Post
101 The Most Promising COVID-19 Vaccine Candidates In The Pipeline To Watch Out For Visit Post
102 Regeneron's cocktail antibody, REGN-COV2; J&J's manufacturing-spree; ObsEva's Yselty top-line studies Visit Post
103 Rising Nontuberculous Mycobacterial Infection Prevalence Poses A Major Public Health Concern Visit Post
104 The Increasing Global Burden of Cytomegalovirus Seroprevalence Visit Post
105 Sarepta & Codiak Inks $72.5M Deal; Invitae to Acquires ArcherDX; Merck announces V114's Phase III result Visit Post
106 HCQ/ CQ failure; AZ/ Catalent’s deal; Sinovac’s CoronaVac and Lilly’s Olumiant trial results Visit Post
107 AbbVie & Genmab’s Collaboration; Lilly's antisense neuro deal; COVID-19 treatment updates; Roche’s partnership with Innovent; Visit Post
108 Alnylam’s lumasiran results; AZ’s oncology drug; Astellas Roxadustat; Evotec’s partnership with ABL Visit Post
109 Eli Lilly's COVID-19 Antibody trial; Approval for Oriahnn; Gilead's Remdesivir Clinical Trials result; Russia approves Avifavir to treat Covid-19 Visit Post
110 Algernon's NP-120; FDA nod to 4DMedical tool; SaNOtize's NORSTM trial; Pole's capital increase Visit Post
111 Keeping a track on COVID-19 through Wearable Technology Visit Post
112 Moderna's COVID-19 Vaccine; Quidel's Lyra gets EUA from FDA; Neurotrope and Metuchen Pharma Announced Merger Agreement; FDA Approval to Rucaparib; Visit Post
113 Security Breach: A Growing Concern For The Healthcare Industry Visit Post
114 Will there be a second wave of coronavirus? Visit Post
115 Telehealth: Opportunities and Hurdles in Virtual Healthcare Market Visit Post
116 In the race to fight SARS-CoV-2: Merck, ISB; ViiV; Genalyte gears up Visit Post
117 Potential Diagnostic solutions that may significantly contribute to COVID-19 detection Visit Post
118 COVID19 pipeline advances as Novartis begins phase III trial of hydroxychloroquine; and advancements in RCC, and HER2 positive breast cancer market Visit Post
119 Novel coronavirus crumbles down as soon as it lands on copper Visit Post
120 Supply shortage: Why ventilators are in demand amid the Coronavirus crisis Visit Post
121 In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit Visit Post
122 Is Hydroxychloroquine the answer to all the COVID-19 questions? Visit Post
123 AstraZeneca targets for COVID-19 antibody trial; Arrakis, Roche team up; GSK, AstraZeneca launch testing lab, U.S. government funds OraSure Visit Post
124 COVID-19 crisis can prove to be a catalyst for Artificial Intelligence in Healthcare Visit Post
125 World Health Day Visit Post
126 Telemedicine: Can it be the future of healthcare? Visit Post
127 J&J's COVID-19 Vaccine; GigaGen COVID-19 therapy; FDA approved Abbott's POC test; Cobra Bio raises $ 3.3 M Visit Post
128 Realm of Pandemics: Were we prepared then? Are we prepared now? Will we be ever prepared? Visit Post
129 FDA permits COVID-19 treatment, Roche's antibiotics pact, Moderna's vaccine, FDA permits Remdesivir, ReCode needs USD 80 Million Visit Post
130 Thermo’s investment; Biohaven’s vazegepant Phase III trial; Cumberland’s aid Visit Post
131 Should you wear contact lenses amid coronavirus outbreak? Visit Post
132 Questions and Answers on the Novel Coronavirus Disease (COVID-19) Visit Post
133 Bridging the gap: Nontuberculous mycobacterium Infections Drug Pipeline Visit Post
134 Nontuberculous Mycobacteria Infection Market: Current status of NTM infection drug discovery and development Visit Post
135 Lack of effective therapy: A major Nontuberculous Mycobacteria Infection Market Driver Visit Post
136 Wuhan Coronavirus: A global emergency Visit Post
137 In a blind race to cure HIV, can Gene therapy be a deal-breaker? Visit Post
138 Marijuana as a treatment approach Visit Post
139 Roche, Sarepta collaborates; FDA approval for Merck’s Ervebo, and Allergan’s Ubrelvy Visit Post
140 National Influenza Vaccination Week Visit Post
141 World AIDS Day- 2019 Visit Post
142 Antimicrobial resistance crisis: A global need for antibiotic awareness Visit Post
143 Onychomycosis therapeutics market: Impact of new topical anti-fungal drugs Visit Post
144 EU’s labels Nirogacestat an Orphan drug; FDA Approves First Smallpox, Monkeypox Vaccine; Evotec and Takeda collaborates to discover clinical candidates Visit Post
145 NMPA approves ALS treatment Edavarone; GSK ends development of Ebola vaccines; Vesselon Acquires FDA-Approved Imagent Visit Post
146 HIV Treatment Landscape and A New Approach Visit Post
147 Frightening Surge in HIV-drug Resistance: The Biggest Challenge Ahead Visit Post
148 Global Hepatitis B Market Size Visit Post
149 World Hepatitis Day Visit Post
150 Is it Okay to take Antibiotics without a prescription? Visit Post
151 Is Parainfluenza virus contagious? Visit Post
152 Beware! Season of Lyme has come Visit Post
153 Acute Bacterial Skin and Skin Structure Infections Emerging Therapies Visit Post
154 ABSSSI Current Therapeutic Market Visit Post
155 GSK to spend $100M; Lilly sell; Sherlock Bio raises $31M; Deerfield, UIC to foster research Visit Post
156 World Malaria Day Visit Post
157 Notizia Visit Post
158 The Business Cocktail Visit Post
159 World Tuberculosis Day Visit Post
160 ColdZyme inactivates viruses; Med for rare genetic disease; Common oral bacteria accelerate Colon cancer; CEPI and CureVac to develop an mRNA vaccine; Celastrol’s effectiveness Visit Post
161 Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate; Blaze Bioscience nets $5M Visit Post
162 CRISPR proves to be a blessing for LASSA fever Visit Post
163 Notizia Visit Post
164 WORLD AIDS DAY - 2018 Visit Post
165 Cholera vaccine delivered; Rice-inspired breakthroughs; International partnerships Visit Post
166 Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug Visit Post
167 Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a helping hand Visit Post
168 Notizia Visit Post
169 Notizia Visit Post
170 SNIPPET Visit Post
171 AZ dragout Entasis; Sierra remunerates Gilead; Principia raises; Harbour BioMed and Kelun pen deal Visit Post
172 The Business Cocktail(Therapeutics) Visit Post
173 Parkinson's and tuberculosis shares a common protein that could provide better drugs for both Visit Post
174 Potential cure for Common cold Visit Post
175 Notizia Visit Post
176 Gilead Sciences  launched a highly effective hepatitis C drug Sovaldi Visit Post
177 Business Cocktail Visit Post
178 Notizia Visit Post
179 Notizia Visit Post
180 Notizia Visit Post
181 Regeneron/Sanofi’s PD-1 drug candidate; Zika targeting drugs and vaccines developments; CMO of Achillion will leave this month; Lincoln's anti-malarial drug Visit Post
182 Human Papillomavirus (HPV) Prophylaxis– Expected to see a steady growth from 2015-2025 Visit Post
183 Dengvaxia study; Opdivo racks up; FDA issues plant; Teva's Rimsa fraud; Mission bags Fox grant Visit Post
184 Business Cocktail Visit Post
185 Antibiotic Resistance: The Big Challenge of Healthcare Industry Visit Post
186 Hepatitis C drugs re-energize global fight over patents Visit Post
187 Vulvovaginal Candidiasis Visit Post
188 Cytomegalovirus infection Market Visit Post
189 Science Events of the Year Visit Post
190 CDC study reveals; Jevtana receives yes; Herantis secures; Immuno-oncology is not cost-effective Visit Post
191 Aurobindo’s net profit; LLS selects; Eli Lilly secures; DNA vaccine against Zika Visit Post
192 Merck’s Antibody for Clostridium Difficile Visit Post
193 Biosimilar Market in India Visit Post
194 Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV Visit Post
195 Dengvaxia: Boon for Dengue Visit Post
196 Sun Pharma & ICGEB announce collaboration; Boehringer Ingelheim and Lupin Sign deal; Daiichi Sankyo Announces; Catalent Pharma Solutions partners with Samsung Bioepis; Celltrion Healthcare and Teva enters into exclusive business collaboration agreement Visit Post
197 FDA Approves STELARA; Novartis announces AMG 334; AbbVie's HCV Regimen; PaizaBio Gains CFDA Approval; WuXi Biologics completes construction Visit Post
198 FDA grants approval; Sanaria receives fast-track designation; Sanofi and Regeneron’s next blockbuster; Allele receives NIH grant Visit Post
199 Sygnis AG and ECACC Collaboration; BioNTech and Genentech Partnership; Partnership between Zydus Cadila and Takeda; Global Agreement between Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Visit Post
200 Futuristic Customizable RNA Vaccine Visit Post
201 Chimeric Antigen Receptor T cell Immunotherapy Market Analysis and Forecast Visit Post
202 DelveInsight launches Indication Active Pharmaceutical Ingredient (API) Reports Visit Post
203 DelveInsight’s Infectious disorders based Gene Therapy Reports Visit Post
204 Infectious Disease and Vaccines Pipeline Reports Visit Post
205 Ebola Virus Drugs Approved or Still in Pipeline. What’s the mystery? Visit Post